Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 expression + STK11 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

HER-2 positive + PD-L1 expression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

PD-L1 overexpression + CD8 overexpression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

STK11 expression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

STK11 negative + LGALS3 overexpression (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

STK11 underexpression (0)

PD-L1 expression (356)

PD-L1 overexpression (181)

PD-L1 underexpression (46)

PD-L1 negative (28)

HER-2 negative + PD-L1 expression (12)

HER-2 positive + PD-L1 expression (3)

HR negative + PD-L1 expression (2)

MSLN overexpression + PD-L1 overexpression (2)

PD-L1 expression + CD68 positive (2)

PD-L1 expression + HER-2 overexpression (2)

PD-L1 expression + PVR expression (2)

PD-L1 overexpression + CD8 overexpression (2)

TTF1 expression + PD-L1 expression (2)

miR-625-5p underexpression + PD-L1 overexpression (2)

STK11 expression (2)

AXL overexpression + PD-L1 expression (1)

CGAS overexpression + PD-L1 overexpression (1)

CMTM4 expression + PD-L1 expression (1)

CMTM6 expression + PD-L1 expression (1)

CMTM6 overexpression + PD-L1 overexpression (1)

CXCL12 expression + PD-L1 underexpression (1)

HLA-A underexpression + PD-L1 expression (1)

HR positive + PD-L1 expression (1)

IGFBP2 overexpression + PD-L1 overexpression (1)

MHC-II overexpression + PD-L1 negative (1)

MHC-II overexpression + PD-L1 underexpression (1)

NKX2-1 expression + PD-L1 expression (1)

NR1H4 overexpression + PD‑L1 underexpression (1)

NT5E overexpression + PD-L1 expression (1)

PD-1 underexpression + PD-L1 overexpression (1)

PD-L1 expression + CD14 positive (1)

PD-L1 expression + CD47 expression (1)

PD-L1 expression + CD8 negative + GZMB negative (1)

PD-L1 expression + CD8 positive (1)

PD-L1 expression + CTLA4 expression (1)

PD-L1 expression + MTOR overexpression (1)

PD-L1 expression + REV3L overexpression (1)

PD-L1 overexpression + APOBEC3B overexpression (1)

PD-L1 overexpression + CCL5 overexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

PD-L1 overexpression + ER positive (1)

PD-L1 overexpression + GZMA overexpression (1)

PD-L1 overexpression + LAG3 expression + CTAG1B expression (1)

PD-L1 overexpression + PD-L2 underexpression (1)

PD-L1 overexpression + SOX2 overexpression (1)

RBM17 expression + PD-L1 expression (1)

RET positive + PD-L1 overexpression (1)

SNX20 overexpression + PD-L1 overexpression (1)

STK11 underexpression + PD-L1 overexpression (1)

TFRC overexpression + PD-L1 underexpression (1)

TNFSF4 overexpression + PD-L1 overexpression (1)

TTF1 expression + PD-L1 overexpression (1)

STK11 negative + LGALS3 overexpression (1)

HER-2 negative + HR negative + PD-L1 expression (0)

PD-L1 expression + HER-2 expression (0)

PD-L1 expression + LAG3 expression (0)

PD-L1 expression + TTF1 expression (0)

TMB + PD-L1 expression (0)

STK11 underexpression (0)

›

1year

A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation (MTCS 2023)

TBD

1 year ago

P2 data • PD(L)-1 Biomarker • IO biomarker

|

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)

|

PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation • KRAS G12C + PD-L1 expression • PD-L1 expression + STK11 mutation

|

opnurasib (JDQ443)

over1year

A phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation. (ASCO 2023)

Reused with permission. Clinical trial information: NCT05445843.

over 1 year ago

P2 data • PD(L)-1 Biomarker • IO biomarker

|

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)

|

PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation • PD-L1 expression + STK11 mutation

|

opnurasib (JDQ443)

almost2years

A Phase II trial of JDQ443 in KRAS G12C-mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation (AACR 2023)

Other secondary endpoints include progression-free survival, overall survival, safety, pharmacokinetics, and pt-reported outcomes. A comprehensive biomarker strategy aims to investigate predictors of treatment response and resistance in the study population.

almost 2 years ago

P2 data • PD(L)-1 Biomarker • IO biomarker

|

PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)

|

PD-L1 expression • KRAS mutation • KRAS G12C • STK11 mutation • KRAS G12 • KRAS mutation + STK11 mutation • PD-L1 expression + STK11 mutation

|

opnurasib (JDQ443)